ZENEO® Midazolam earns the FDA orphan drug designation for the treatment of status epilepticus
The American Food and Drug Administration (FDA) has granted Orphan Drug Designation to ZENEO® Midazolam for the treatment of status epilepticus (epileptic seizure lasting longer than 5 minutes).
The orphan designation for ZENEO® Midazolam improves Crossject’s international visibility and gives impetus to its current negotiations for partnerships with pharmaceutical laboratories.
Presse kit 2018
ZENEO® is the manifestation of Crossject’s expertise in the needle-free injection of drugs, an expertise unmatched elsewhere in the world. The device is the result of nearly 20 years of R&D and it has earned close to 400 patents. For patients, ZENEO® enables the simple, rapid, needle-free, intramuscular or subcutaneous self-administration of treatments in a ready-to-use package.
The company’s portfolio currently contains eight products in advanced stages of development, seven of which are for urgent or life-threatening situations. Crossject aims to become the world leader in selfadministered emergency treatments
ZENEO® receives the 2017 JANUS Prospective Award
Crossject is proud to announce that ZENEO® received the 2017 JANUS Prospective award from the French Institute of Design. This award recognizes the forward-looking vision of Crossject and the determination of its founder, Patrick Alexandre, to overcome the numerous challenges in the device’s conception and particularly its ergonomics, a core aspect present from the start and developed in collaboration with patients and healthcare professionals.
Promoted by the French Ministry for the Economy and Finance, this JANUS award reinforces Crossject’s ambition of becoming the world’s leading pharmaceutical laboratory for self- administered emergency products.